Our Strategy

The Osteosarcoma Institute has prioritized three areas for investment:

Immediate Clinical Impact

Identify effective new drugs and drug combinations by funding clinical trials in recurrent and metastatic osteosarcoma.

  • Typically Phase II, signal-finding trials designed to get quick answers to important questions and learn from both successes and failures. To that end, we will also consider providing support for correlative studies in existing trials.
  • We expect to announce our first grant enabling such a trial this spring.
  • A new Request for Proposal (RFP) will be issued this summer.

Fill Gaps in Scientific Understanding

Gain insight by identifying and funding pre-clinical studies of translationally-relevant unknowns that are impeding progress.

  • Typically one-year grants with a renewal option. We expect to announce our first grant for a study in metastasis in osteosarcoma in early summer.
  • A new RFP will be issued this summer.

Gain insight by identifying and funding pre-clinical studies of translationally-relevant unknowns that are impeding progress.

  • Typically one-year grants with a renewal option. We expect to announce our first grant for a study in metastasis in osteosarcoma in early summer. 
  • A new RFP will be issued this summer.

Osteosarcoma Outreach

Raise awareness of osteosarcoma in important communities

  • Patients and families – establish a clearinghouse of clinical and research resources
  • Drug developers and regulators – Encourage investment in research and development of new osteosarcoma therapies
  • Build the case for pharma and biotech industry investment in osteosarcoma as a viable path to approval for new agents
  • Engage the FDA to provide clear approval criteria for new drugs and drug combinations

The OSI is committed to transparency in its investment processes, and to rapid reporting of results.